Research & Development

Affini-T Therapeutics secures funding to advance T cell therapies

Biotechnology firm Affini-T Therapeutics has raised $175m in an oversubscribed financing round for advancing T cell therapies for solid tumour patients with oncogenic driver mutations.

Triumvira Immunologics raises funds for T-cell therapy programmes

Triumvira Immunologics has completed an extension of Series A financing, which brings the total round to nearly $100m, for supporting the continued preclinical and clinical development of its T cell Antigen Coupler (TAC)-T cell therapy programmes.

Sanofi, Blackstone partner to advance multiple myeloma treatment

Sanofi has announced a collaboration with investment management firm Blackstone to advance an innovative treatment for multiple myeloma.

Erasca, Eli Lilly partner for colorectal cancer therapy trial

Erasca and Eli Lilly and Company have signed a clinical trial partnership and supply agreement to evaluate ERAS-007, an oral ERK1/2 inhibitor, in combination with Eli Lilly's anti-EGFR antibody cetuximab (ERBITUX).

Salubris secures funding to advance complex biologics for various diseases

Salubris Biotherapeutics has secured $32m in financing from Shenzhen Salubris Pharmaceuticals to advance its new complex biologics for oncology, cardiovascular and neurodegenerative diseases.

Helsinn, BridgeBio update infigratinib collaboration for oncology indications

Helsinn Group has announced an update to its existing collaboration with BridgeBio Pharma to develop, produce and commercialise infigratinib for oncology indications in the US.

Epsilogen to develop antibodies for cancer treatment with new funding

Epsilogen has raised $41.011m (£30.75m) in a Series B funding round led by new investor Novartis Venture Fund to further develop IgE-based antibody candidates for cancer treatment.

Rondo raises funding to advance solid tumour immuno-oncology platform

Biopharmaceutical firm Rondo Therapeutics has raised $67m in a Series A financing round to advance next-generation immuno-oncology platform to treat solid tumours.

ENA Respiratory partners with COPD Foundation for antiviral nasal spray

ENA Respiratory has collaborated with not-for-profit organisation COPD Foundation for the development of INNA-051, a pan-antiviral nasal spray, for chronic lung diseases patients.